Abeona Therapeutics (ABEO)

• Market cap: $398M
• 1 day: -1.97%
• 5 days: 8.55%
• 1 month: 30.22%
• 3 months: 42.16%
• 6 months: 36.86%
• Year to date: 31.45%
• 1 year: 19.32%
• 5 years: -80.34%
• 10 years: -88.22%
• Sector: Healthcare
• Industry: Biotechnology

About: Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.

Employees: 226